Publication: Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme
Issued Date
2016-12-01
Resource Type
ISSN
1573904X
07248741
07248741
Other identifier(s)
2-s2.0-84982938309
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Research. Vol.33, No.12 (2016), 2891-2903
Suggested Citation
Chawan Manaspon, Norased Nasongkla, Khuanjit Chaimongkolnukul, Pinunta Nittayacharn, Ketpat Vejjasilpa, Kanchana Kengkoom, Atthaporn Boongird, Suradej Hongeng Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme. Pharmaceutical Research. Vol.33, No.12 (2016), 2891-2903. doi:10.1007/s11095-016-2011-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42804
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme
Other Contributor(s)
Abstract
© 2016, Springer Science+Business Media New York. Purpose: SN-38, a potent chemotherapeutic drug, has not been used clinically because of its severe side effects and poor solubility. In this work, we aimed to evaluate the effect of dose and multiple injections of SN-38-loaded polymeric depots on antitumor efficacy and toxicity in vivo. Methods: Preparation and characterization of SN-38-loaded depots were performed and evaluated in vitro using human glioblastoma cell line, U-87MG. Antitumor efficacy with different depot administrations including dose, position of depot injection and number of injections were evaluated in tumor model in nude mice. Results: Depots encapsulated SN-38 with high encapsulation efficiency (~98.3%). High amount of SN-38 (3.0 ± 0.1 mg) was prolonged and controlled release over time and showed anticancer activity against U-87MG cell line in vitro. For one course administration, depots exhibited better antitumor efficacy and reduced toxicity compared to free SN-38. Elevated doses and multiple injections of SN-38-loaded depots and free SN-38 provided greater tumor growth inhibition and animal survival. All animals received SN-38-loaded depots were well tolerated and survived while most of those received free SN-38 died at day 30. Free SN-38 showed severe toxic effect compared to minimal toxicity from SN-38-loaded depots which was due to lower SN-38 level in systemic circulation. Fluorescence imaging and histopathology confirmed that SN-38 released from depots was detected throughout tumors 35 days post administration. Conclusions: SN-38-loaded depots were proved as a promising new treatment for highly invasive glioblastoma multiforme with low acute toxicity due to controlled release of SN-38.